I now have sufficient information for a calibrated assessment. Here is the final consolidated review.

---

## Summary

This paper proposes an end-to-end framework for multi-view diabetic retinopathy grading that replaces expensive external lesion annotations with self-derived lesion proposals. Two modules are introduced: GALP (Grade-Activated Lesion Proposal) generates lesion proposals from stage-wise auxiliary classifiers via CAM-based evidence maps and Top-K selection, and LGRF (Cross-View Lesion Expert Guided Regional Fusion) uses a gated mixture-of-experts with Top-K weighted cross-view attention to fuse proposals across views. The method is evaluated on the four-view MFIDDR and two-view DRTiD benchmarks, showing competitive performance against both end-to-end and externally informed methods.

## Strengths

- **Self-derived proposals achieve competitive accuracy without external annotations.** The lesion-free variant (83.9% accuracy on MFIDDR) surpasses all purely end-to-end baselines (best prior: ETMC 81.5%) and matches or exceeds several externally informed methods (e.g., LFMVDR with lesion at 82.2%, CVSA with vessel at 82.6%). On DRTiD, the end-to-end method (76.0%) outperforms the annotation-dependent CrossFIT (75.6%). This directly supports the core claim that self-generated proposals can reduce annotation reliance.

- **Ablation confirms both GALP and LGRF contribute measurably.** Table 4 shows consistent degradation when removing GALP (83.9 → 82.7%), LGRF (83.9 → 82.3%), or the expert pool (83.9 → 82.6%). The ablation is cleanly designed — each variant tests a specific component — and the drops are non-trivial (1.2–1.6 points on accuracy).

- **Generalization to a different multi-view setting.** On DRTiD (2-view), the method outperforms all compared methods including those requiring optic disc and macula coordinates, providing cross-dataset and cross-annotation-regime evidence.

- **Systematic hyperparameter analysis.** Figure 3 evaluates retention ratio α, number of routed experts K₂, and total experts M, identifying optimal settings (α=0.5, K₂=2, M=6) and showing the method is not overly sensitive to these choices.

- **Grade-wise improvements on challenging categories.** With lesion input, the method achieves the best F1 on Grade 2 (65.2%) and Grade 3 (74.8%) among all compared methods, demonstrating sensitivity to mid-grade pathology where micro-lesions matter most.

## Weaknesses

### Major

- **No qualitative validation that proposals correspond to actual lesions.** The paper's central motivation is that GALP generates "lesion proposals" that serve as surrogates for expert annotations. Yet no visualization is provided — no overlay of Grade-Activated Evidence Maps on fundus images, no comparison with ground-truth lesion masks, no analysis of what the Top-K regions actually capture. Without this, the mechanism is a black box: the selected regions could be picking up illumination gradients, background artifacts, or other grade-correlated but non-lesion patterns. The paper's claims about interpretability are also entirely unsubstantiated. This is a major methodological gap that weakens the core narrative.

- **Backbone-controlled comparison to prior methods is absent.** The headline comparisons pit the proposed method (Swin-B backbone) against published results from methods using different backbones (e.g., RETFound uses ViT-Large, MVCINN uses a custom hybrid, MVCNN uses ResNet50/VGG19). The gains over end-to-end baselines (e.g., 83.9% vs 80.1% for MVCINN) are therefore uninterpretable as evidence for the proposed modules — they could be substantially driven by the stronger backbone. The ablation (Table 4) credibly isolates the modules' contributions *within* the Swin-B framework, so the internal evidence is solid. But the paper's central external claim — matching/surpassing prior methods without annotations — rests on comparisons that are not held on equal architectural terms. Re-implementing the strongest baselines with the same backbone would directly address this.

### Minor

- **No error bars, confidence intervals, or statistical tests.** All results are single numbers. On DRTiD the margin over CrossFIT is only 0.4% (76.0 vs 75.6); on MFIDDR the w/o-lesion variant (83.9%) is 0.3% below the best externally informed method WGLIN (84.2%). Without variance estimates, the reader cannot assess whether these differences are meaningful or within noise. While single-run reporting is common in this benchmark setting, the small margins make this omission more consequential.

- **Missing a simple multi-view Swin-B baseline without either module.** The ablation removes GALP or LGRF one at a time, but "w/o GALP" still uses LGRF's expert routing and "w/o LGRF" still uses GALP's proposals. A baseline that strips both modules — a plain multi-view Swin-B with standard cross-attention on all tokens — would cleanly isolate the combined contribution. The current design is informative but incomplete.

- **No report of model size (parameters) or inference cost.** The MoE with 6 transformer experts per stage (4 stages) per view could be substantial. Reporting parameters and FLOPs would help assess practical viability, especially when comparing to simpler baselines.

### Trivial

None.

## Nice-to-Haves

- **Failure case analysis.** The CAM-based proposals depend on the auxiliary classifier being reasonably accurate for early-stage lesions. The paper does not discuss settings where the auxiliary head is inaccurate and proposals miss critical regions.
- **The paper could clarify whether reported baseline numbers are taken from original papers or re-implemented under the same preprocessing.** The high variance in Grade 4 F1 among baselines (0.9% for ETMC to 64.1% for CVSA) suggests sensitivity to preprocessing or split details that is not discussed.

## Removed Points

The following are removed (with justifications) from the Harsh Critic / Strength Finder inputs:

- **"Microaneurysms are under-represented claim lacks citation"** — The paper states this as a general motivation (not a quantitative claim requiring a specific citation), and the broader context is well-referenced. Removing as overly pedantic.
- **"Equation (3) notation is ambiguous"** — The notation `\mathbf{w}_{s_n, c}^{(s_n)}` is standard for class-specific weight vectors in CAM methods. The superscript clarifies the stage index; this is typical notational density, not an error. Removing as a nitpick.
- **"The paper doesn't make explicit that the predicted grade is used"** — The paper states "the class-specific weight vector for the predicted grade" (Sec 3.2), which is explicit. The critic's concern is addressed by the paper as written.
- **Strength Finder's claim about Grade 4 F1 being "the best among all compared methods"** — Incorrect. CVSA achieves F1=64.1% on Grade 4, which is higher than the paper's with-lesion variant (51.6%). This strength is factually wrong and removed.
- **"Models that were not originally designed for this exact dataset split"** — The paper explicitly follows prior work's experimental protocol and splits. This criticism is speculation about preprocessing differences without evidence.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Provide qualitative evidence that proposals correspond to lesions.** Show overlays of the Top-K proposal regions on fundus images, ideally with ground-truth lesion masks for a subset. Without this, the central mechanism is unvalidated and the interpretability claim is empty.
2. **Re-implement the strongest baselines** (e.g., MVCINN, CVSA's non-annotated variant) with the same Swin-B backbone and training pipeline to isolate the effect of the proposed modules from backbone choice.
3. **Add a simple baseline** — multi-view Swin-B with standard cross-attention (no GALP, no LGRF, no expert routing) — to complete the ablation.
4. **Report confidence intervals** (e.g., via bootstrapping or multiple seeds) for the key results, particularly where margins are small.
5. **Report model parameters and approximate FLOPs** to contextualize the computational cost of the MoE design.

## Score and Decision

### Calibration Report

**Round 1 (Bracketing):** Queried multi-view/medical DR grading papers across three score bands. Weak band (avg < 3.5) produced mostly out-of-domain papers (aircraft distance, stereo matching) with scores 2.33–3.40. Middle band (3.5–7.5) produced relevant anchors: Eye Fairness (5.50), M4oE (5.75), TEF (6.25), DSPFusion (4.60). Strong band (7.5+) produced papers with avg scores 7.60–8.00 but topically dissimilar (3D generation, view synthesis). **Initial bracket: 5.0–6.5.**

**Round 2 (Narrowing):** Queried medical/deep-learning papers within (4.5–6.0) and (6.0–7.5). Read full reviews for key anchors:

| Anchor | Score | Round | Comparison |
|--------|-------|-------|------------|
| Lv9KZ5qCSG (Eye Fairness) | 5.50 | R1 | Dataset paper with fairness method; similar evidential gaps (no significance testing, baseline concerns). Paper under review has stronger technical novelty but missing qualitative validation is a bigger gap. |
| NJxCpMt0sf (M4oE) | 5.75 | R1 | Multi-modal MoE medical paper; similar gaps (no error bars, baseline comparison concerns, no compute reporting). Paper under review has comparable technical depth and similar evidential quality — slightly weaker on validation but slightly stronger on ablation. |
| M3kBtqpys5 (TEF) | 6.25 | R1 | Multi-view classification with NAS; more extensive experiments. Paper under review has weaker comparative evidence but stronger module-level ablation. |
| RJDjSXNuAZ (Weakly Supervised Virus) | 5.50 | R2 | Weakly supervised medical detection; comparable evidence quality. Paper under review has more architectural novelty. |
| zcTLpIfj9u (Future-Guided Pretraining) | 6.33 | R2 | Stronger medical imaging paper with clear contribution. Paper under review is weaker — the two major evidential gaps (qualitative validation, backbone control) are more significant than that paper's limitations. |

**Final score:** The paper is positioned between the 5.50 and 5.75 anchors. It has genuine technical novelty and solid internal ablation evidence, but the two major weaknesses (no qualitative validation of the core proposal mechanism, and uncalibrated backbone comparisons for external claims) prevent it from reaching the 6+ level. **Score: 5.5.**

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Accept</decision>